Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers.
Adult
Aged
Diffusion Magnetic Resonance Imaging
/ methods
Diffusion Tensor Imaging
/ methods
Disease Progression
Female
Frontotemporal Dementia
/ genetics
Gray Matter
/ pathology
Heterozygote
Humans
Male
Middle Aged
Mutation
/ genetics
Neurodegenerative Diseases
/ genetics
Neuropsychological Tests
White Matter
/ pathology
tau Proteins
/ genetics
Asymptomatic
Diffusion tensor image
Frontotemporal dementia
Longitudinal
MAPT
Journal
Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
14
02
2019
revised:
07
08
2019
accepted:
11
08
2019
pubmed:
5
10
2019
medline:
9
7
2020
entrez:
5
10
2019
Statut:
ppublish
Résumé
Our aim was to investigate the patterns and trajectories of white matter (WM) diffusion abnormalities in microtubule-associated protein tau (MAPT) mutations carriers. We studied 22 MAPT mutation carriers (12 asymptomatic, 10 symptomatic) and 20 noncarriers from 8 families, who underwent diffusion tensor imaging (DTI) and a subset (10 asymptomatic, 6 symptomatic MAPT mutation carriers, and 10 noncarriers) were followed annually (median = 4 years). Cross-sectional and longitudinal changes in mean diffusivity (MD) and fractional anisotropy were analyzed. Asymptomatic MAPT mutation carriers had higher MD in entorhinal WM, which propagated to the limbic tracts and frontotemporal projections in the symptomatic stage compared with noncarriers. Reduced fractional anisotropy and increased MD in the entorhinal WM were associated with the proximity to estimated and actual age of symptom onset. The annualized change of entorhinal MD on serial DTI was accelerated in MAPT mutation carriers compared with noncarriers. Entorhinal WM diffusion abnormalities precede the symptom onset and track with disease progression in MAPT mutation carriers. Our cross-sectional and longitudinal data showed a potential clinical utility for DTI to track neurodegenerative disease progression for MAPT mutation carriers in clinical trials.
Identifiants
pubmed: 31585367
pii: S0197-4580(19)30289-1
doi: 10.1016/j.neurobiolaging.2019.08.011
pmc: PMC6858933
mid: NIHMS1055307
pii:
doi:
Substances chimiques
MAPT protein, human
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-62Subventions
Organisme : NIA NIH HHS
ID : P30 AG013854
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG045333
Pays : United States
Organisme : NIA NIH HHS
ID : U24 AG021886
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG040042
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG057547
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG019724
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG045390
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS092089
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100620
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG017586
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG063911
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
J Biol Chem. 2001 Jan 5;276(1):529-34
pubmed: 11013246
Neuroimage Clin. 2017 Sep 14;16:595-603
pubmed: 28975068
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
J Neurol Neurosurg Psychiatry. 1993 Jun;56(6):605-14
pubmed: 8509772
Front Aging Neurosci. 2018 Mar 06;10:47
pubmed: 29559904
Glia. 2018 Apr;66(4):813-827
pubmed: 29315804
Nat Rev Neurosci. 2005 Nov;6(11):889-98
pubmed: 16224497
Am J Pathol. 2003 Jan;162(1):213-8
pubmed: 12507904
Acta Neuropathol. 2017 Sep;134(3):459-473
pubmed: 28638989
Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):70-74
pubmed: 26990251
PLoS One. 2012;7(6):e37720
pubmed: 22701578
Alzheimers Dement. 2014 Oct;10(5 Suppl):S354-S363.e1
pubmed: 24418059
Neurobiol Aging. 2019 Apr;76:115-124
pubmed: 30711674
Nat Rev Neurol. 2012 Jan 31;8(3):131-42
pubmed: 22290573
Brain. 2016 Dec;139(Pt 12):3237-3252
pubmed: 27797812
Neurobiol Aging. 2018 Feb;62:191-196
pubmed: 29172163
Lancet. 2015 Oct 24;386(10004):1672-82
pubmed: 26595641
Neurobiol Aging. 2018 Aug;68:68-75
pubmed: 29729423
Ann Neurol. 2015 Jan;77(1):33-46
pubmed: 25363208
PLoS One. 2014 Mar 03;9(3):e90814
pubmed: 24595028
Trends Mol Med. 2002 Dec;8(12):555-62
pubmed: 12470988
Hum Brain Mapp. 2013 Nov;34(11):2747-66
pubmed: 22611035
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7737-41
pubmed: 9636220
Front Neuroinform. 2014 Feb 21;8:8
pubmed: 24600385
J Neuropathol Exp Neurol. 2008 Oct;67(10):963-75
pubmed: 18800011
Neurology. 2014 Jul 8;83(2):e19-26
pubmed: 25002573
Neurobiol Aging. 2014 Jun;35(6):1364-74
pubmed: 24411290
Neurology. 2010 Aug 31;75(9):771-8
pubmed: 20805522
Neuroimage. 2012 Jul 16;61(4):1000-16
pubmed: 22484410
Neurobiol Aging. 2017 Aug;56:172-179
pubmed: 28552181
Neurology. 2010 Apr 20;74(16):1279-87
pubmed: 20404309
J Biol Chem. 2006 Apr 28;281(17):11856-63
pubmed: 16495230
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Nature. 1998 Jun 18;393(6686):702-5
pubmed: 9641683
JAMA Neurol. 2018 Feb 1;75(2):236-245
pubmed: 29197216
Ann Clin Transl Neurol. 2018 Jul 11;5(9):1025-1036
pubmed: 30250860
Lancet Neurol. 2015 Mar;14(3):253-62
pubmed: 25662776
Brain. 2019 Jan 1;142(1):193-208
pubmed: 30508042
Dement Geriatr Cogn Disord. 2000 May-Jun;11(3):123-34
pubmed: 10765042
Alzheimers Res Ther. 2018 May 24;10(1):46
pubmed: 29793546
Neuroimage. 2014 Dec;103:411-426
pubmed: 25109526
Curr Opin Neurol. 2011 Dec;24(6):542-9
pubmed: 21986680
Neuroimage. 2008 Nov 15;43(3):447-57
pubmed: 18692144
Ann Neurol. 1996 Jun;39(6):734-43
pubmed: 8651645
Brain. 2008 Nov;131(Pt 11):2957-68
pubmed: 18829698
Biol Psychiatry. 2000 Jun 15;47(12):1056-63
pubmed: 10862805